Literature DB >> 22127400

Aliskiren-associated acute kidney injury in a patient with pre-existing chronic kidney disease and dilated cardiomyopathy.

Junji Yamauchi1, Yugo Shibagaki, Keita Uehara, Takashi Yasuda, Kenjiro Kimura.   

Abstract

We report a case of acute kidney injury (AKI) caused by a novel direct renin inhibitor, aliskiren. A 43-year-old Japanese man with dilated cardiomyopathy on cardiac resynchronization therapy with defibrillator and chronic kidney disease (CKD) was started on aliskiren in addition to enalapril, carvedilol, furosemide, and spironolactone for worsening cardiac function suggested by the elevation of serum brain natriuretic peptide. After 1 month, he noticed general malaise, loss of appetite and his serum creatinine level increased from 2.0 to 7.24 mg/dL. He had no evidence of exacerbation of hemodynamic instability (heart failure or hypotension) or post-renal cause of AKI. Although a cessation of aliskiren did not ameliorate AKI, renal function returned to baseline after withholding enalapril. Careful monitoring is necessary when aliskiren is used in patients with CKD and/or significant systolic dysfunction since it can cause normotensive ischemic AKI, especially when there is a concomitant use of other renin-angiotensin-aldosterone system inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22127400     DOI: 10.1007/s10157-011-0566-2

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  9 in total

1.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

Review 2.  Normotensive ischemic acute renal failure.

Authors:  J Gary Abuelo
Journal:  N Engl J Med       Date:  2007-08-23       Impact factor: 91.245

3.  Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.

Authors:  David M Kent; Tazeen H Jafar; Rodney A Hayward; Hocine Tighiouart; Marcia Landa; Paul de Jong; Dick de Zeeuw; Giuseppe Remuzzi; Anne-Lise Kamper; Andrew S Levey
Journal:  J Am Soc Nephrol       Date:  2007-05-02       Impact factor: 10.121

4.  Aliskiren-associated acute renal failure with hyperkalemia.

Authors:  R M Venzin; C D Cohen; M Maggiorini; R P Wüthrich
Journal:  Clin Nephrol       Date:  2009-03       Impact factor: 0.975

5.  Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction.

Authors:  Sadayoshi Ito; Noriko Nakura; Stephanie Le Breton; Deborah Keefe
Journal:  Hypertens Res       Date:  2009-11-20       Impact factor: 3.872

6.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

7.  Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.

Authors:  John J V McMurray; Bertram Pitt; Roberto Latini; Aldo P Maggioni; Scott D Solomon; Deborah L Keefe; Jessica Ford; Anil Verma; Jim Lewsey
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

8.  Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.

Authors:  Naomi D L Fisher; A H Jan Danser; J Nussberger; William P Dole; Norman K Hollenberg
Journal:  Circulation       Date:  2008-06-16       Impact factor: 29.690

9.  Acute kidney injury increases risk of ESRD among elderly.

Authors:  Areef Ishani; Jay L Xue; Jonathan Himmelfarb; Paul W Eggers; Paul L Kimmel; Bruce A Molitoris; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2008-11-19       Impact factor: 14.978

  9 in total
  3 in total

1.  Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure.

Authors:  Hitesh M Soni; Praful P Patel; Savan Patel; Akshyaya C Rath; Aviseka Acharya; Harshkant D Trivedi; Mukul R Jain
Journal:  Indian J Pharmacol       Date:  2015 Jan-Feb       Impact factor: 1.200

Review 2.  The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling.

Authors:  Maricica Pacurari; Ramzi Kafoury; Paul B Tchounwou; Kenneth Ndebele
Journal:  Int J Inflam       Date:  2014-04-06

3.  Identification of Structural Features for the Inhibition of OAT3-Mediated Uptake of Enalaprilat by Selected Drugs and Flavonoids.

Authors:  Yao Ni; Zelin Duan; Dandan Zhou; Shuai Liu; Huida Wan; Chunshan Gui; Hongjian Zhang
Journal:  Front Pharmacol       Date:  2020-05-28       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.